Apollo Hospitals Enterprise Ltd Q3 FY2025 Concall Summary

Key Takeaways

• All-round mid-teen growth with margin expansion: All three business segments delivered mid-teen revenue growth, while hospital EBITDA margins reached 24.1% driven by high-end specialty mix and payer optimization.
• Bangladesh disruption bottoming out: A 1.5% revenue headwind from the Bangladesh patient drop, concentrated in Chennai, is expected to have troughed, with replacement flows being built from new international markets.
• Digital business deliberately recalibrated: Apollo 24/7 shifted from GMV-chasing to an EBITDA-neutral path, cutting the GMV target from INR 4,000 crore to ~INR 3,100 crore and targeting breakeven by Q2/Q3 FY26.
• Insurance foray now fully licensed: All IRDAI approvals are in hand, with product rollout in March and at least 3 life and 3 health insurers live on the platform by April, adding a new margin layer to the digital business.
• What to watch next quarter: The pace of international patient recovery from replacement markets, the insurance GMV ramp from April, and whether the 24/7 recalibration stays on its 5-quarter breakeven timeline.

Hospital Business: Volume, Mix & Margins

• CONGO specialties powering growth: Cardiac, Oncology, Neurosciences, Gastro and Orthopedics grew IP volumes at 10.35%, more than double the overall 5% pace, with Oncology revenue up 25%, Neurosciences 23% and Gastro 20%.
• Payer mix shifting favorably: Cash and insurance patients now account for 83% of inpatient revenue, up 15% YoY, a deliberate optimization that supports ARPOB growth alongside high surgical volumes and an enhanced clinical case mix.
• ARPOB trajectory set: Management expects ARPOB growth to compound at 6-7% going forward, driven by the structural mix shift toward higher-value specialties rather than price increases alone.
• Length of stay intentionally compressed: The group reduced average length of stay from 3.34 to 3.29 days, particularly in the top 6 bed-constrained units, using operational efficiency and Health IT to free capacity without adding beds.
• Occupancy has room to run: Current occupancy of 68% is expected to improve to 72-73% before new beds open, with the Bangladesh revenue gap being filled by patient flows from Indonesia, Iraq, Iran, Sri Lanka, the Middle East and Africa.
• Bangladesh impact concentrated and troughing: The 1.5% group revenue hit was a 3%+ impact in Chennai and Tamil Nadu specifically, since most Bangladesh patients traveled there. Foreign patients carry a 15-20% pricing premium, so the mix effect amplified the revenue loss. Management believes the bottom has been reached.

Madhu Sasidhar: "Occupancy is probably not a perfect metric to measure us by, because there are so many numbers that go into it."

New Capacity: Timeline & Breakeven Expectations

• Commissioning cadence locked: Pune and Calcutta hospitals open in H1 FY26, Hyderabad and Gurugram closer to end of FY26, with Malleswaram and Mysore dates still being finalized. Defense Colony Delhi, a dedicated cancer hospital, opens early next year.
• Bed addition split across two years: Of the 1,737 new beds being commissioned, 50% come online in FY26 and 50% in FY27.
• Breakeven expected rapidly: Calcutta and Delhi are each expected to reach EBITDA breakeven in less than 12 months. Calcutta benefits from an existing facility already running above 80% occupancy and a strong oncology program, with the new hospital just 17-18 km away.
• Margin dilution contained: New hospital openings are expected to impact overall hospital margins by no more than 100 bps, keeping the net margin around 24% even as the new facilities ramp.
• Longer-dated projects underway: Work has started on the OMR facility, Worli begins in the next 3 months, and all other commissioned projects are expected to come online in 3-4 years.

Suneeta Reddy: "We do believe that in all of these facilities, we will achieve breakeven very quickly, because we already have an existing presence and brand Apollo is well known."

Apollo 24/7: Recalibration from Growth to Profitability

• GMV target deliberately cut: The original INR 4,000 crore GMV ambition has been recalibrated to approximately INR 3,100 crore, with the focus shifting entirely to building an EBITDA-neutral model within 5 quarters, by Q3 of the coming financial year.
• Breakeven math defined: The digital business needs INR 900-1,000 crore of GMV to break even, with e-Pharmacy contributing around INR 180 crore. Current GMV stands at INR 760-780 crore.
• Cost base stabilizing: Operating costs of approximately INR 110 crore per quarter are expected to stay around current levels, with some manpower rationalization offset by investment in the insurance business.
• Operating model pivoted to recurring relationships: The business has shifted from marketing-spend-driven acquisition to building an omni-channel chronic and mom/baby customer base, reducing paid marketing and ramping the Circle loyalty program, which already has nearly 0.5 crore paid customers.
• 19-minute delivery expanded cautiously: The proposition rolled out to 4 cities in Q3, but unit economics breakeven has been pushed back by roughly a quarter as the model is refined.
• Margin trajectory mapped: Management expects digital margins to hit 18-20% in the quarter when breakeven is achieved, up from 13.8% in Q3 FY25 and 10.4% in Q3 FY24, supported by insurance and value-added services.

M. Balakrishnan: "Instead of GMV, our focus shifted to ensuring that we are able to build EBITDA-neutral model by Q3 coming financial years. So, we have given ourselves 5 quarters. So, we are on goal."

Insurance: A New Margin Layer

• Fully licensed and launching: All IRDAI approvals, including the corporate agency license and digital clearances, have been obtained. Product rollout begins in March, and by April at least 3 life insurance and 3 health insurance businesses will be operational on the Apollo 24/7 platform.
• OPD insurance next in line: Management intends to enter OPD insurance by the end of Q1 next financial year, which would create its own margin structure and act as a demand generator for the pharmacy business.
• Distribution partnerships multiplying: Traction with SBI, ICICI and other financial institutions is designed to access a larger customer base without incurring huge acquisition cost. A co-branded health card with SBI Cards, similar to the Amazon ICICI Card program, is in the works.
• Margin expansion expected: Insurance carries large margin percentages, and management expects it to support further improvement in the digital business margin profile as it scales.

AHLL & Digital Growth: The Next Leg

• AHLL targeting 15-18% growth: Diagnostics and clinics are the two business units being pushed to drive this growth rate over the next couple of years, with clinics also generating significant diagnostics revenue within their setup.
• AHLL margin improvement path set: Current EBITDA of 9.2% is expected to improve by 2 percentage points per year, driven by a business mix shift toward higher-margin Primary Care and diagnostics.
• Digital business expanding beyond metros: Currently 80-85% of digital revenue comes from the top 6 metros. The plan is to replicate the core model in approximately 25 markets over the next 2 years, while also building e-consult integration with hospitals and clinics.
• Digital growth aspiration at 20%+: Management is targeting over 20% growth for the digital business, though the emphasis is on sustainable, profitable expansion rather than the extraordinary growth rates of earlier phases.

Sriram Iyer: "Currently, we are at a 9.2% EBITDA this year. And we definitely, over a longer-term view, we should expect a 2-percentage point in a year, at least to come in."

Healthco Vision & Consolidated Trajectory

• FY27 Healthco targets reaffirmed: INR 25,000 crore revenue with 7-8% EBITDA, up from the current run rate of approximately INR 17,000 crore with 6.5% margin excluding digital losses. The path runs through hospital capacity expansion, digital breakeven and insurance scaling.
• Hospital revenue growth expected to stay mid-teen: Management indicated mid-teen growth should continue for the hospital segment, though it declined to provide specific 3-year guidance when asked, saying it would return with more detail later.
• Other income spike is one-off: Q3 other income of INR 64 crore, versus the INR 37-38 crore run rate in Q1 and Q2, included approximately INR 20 crore from a one-off income tax refund, with the balance from mutual fund interest.
• Microsoft partnership broadened: The collaboration has expanded beyond the earlier narrow cardiac risk prediction scope to bring AI technologies to the bedside for efficacy and efficiency improvements across the hospital network.

Sanjiv Gupta: "We should be hitting anything between 18% to 20% as a margin during that quarter to support the breakeven intent of the organization."

Guidance & Commitments

Key Metrics